Mesenchymal Stem Cells in Fibrotic Disease

Publication date: 3 August 2017
Source:Cell Stem Cell, Volume 21, Issue 2
Author(s): Elie El Agha, Rafael Kramann, Rebekka K. Schneider, Xiaokun Li, Werner Seeger, Benjamin D. Humphreys, Saverio Bellusci
Fibrosis is associated with organ failure and high mortality and is commonly characterized by aberrant myofibroblast accumulation. Investigating the cellular origin of myofibroblasts in various diseases is thus a promising strategy for developing targeted anti-fibrotic treatments. Recent studies using genetic lineage tracing technology have implicated diverse organ-resident perivascular mesenchymal stem cell (MSC)-like cells and bone marrow-MSCs in myofibroblast generation during fibrosis development. In this Review, we give an overview of the emerging role of MSCs and MSC-like cells in myofibroblast-mediated fibrotic disease in the kidney, lung, heart, liver, skin, and bone marrow.

Teaser

Fibrosis is associated with organ failure and is characterized by aberrant myofibroblast accumulation; thus, investigating the cellular origin of myofibroblasts is a promising therapeutic strategy. Here we discuss the emerging role of MSCs and MSC-like cells in myofibroblast-mediated fibrotic disease in the kidney, lung, heart, liver, skin, and bone marrow.


http://ift.tt/2uova7w